Sinopharm Tech Holdings Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

Sinopharm Tech Holdings yıllık ortalama 6.6% oranında kazançlarını artırırken, Hospitality sektöründe kazançlar growing at 11.6% annual. Gelirler azalıyor .

Anahtar bilgiler

6.6%

Kazanç büyüme oranı

10.4%

EPS büyüme oranı

Hospitality Sektör Büyümesi	-9.4%
Gelir büyüme oranı	-15.3%
Özkaynak getirisi	n/a
Net Marj	-62.0%
Son Kazanç Güncellemesi	31 Dec 2023

Yakın geçmiş performans güncellemeleri

Recent updates

Is Sinopharm Tech Holdings Limited's (HKG:8156) Shareholder Ownership Skewed Towards Insiders?

Feb 02

How Much Did Sinopharm Tech Holdings'(HKG:8156) Shareholders Earn From Share Price Movements Over The Last Five Years?

Dec 29

How Should Investors Feel About Sinopharm Tech Holdings' (HKG:8156) CEO Remuneration?

Nov 24

Gelir ve Gider Dağılımı

Sinopharm Tech Holdings nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.

Kazanç ve Gelir Geçmişi

SEHK:8156 Gelir, gider ve kazançlar (HKD Millions )
Tarih	Gelir	Kazançlar	G+A Giderleri
31 Dec 23	47	-29	92
30 Sep 23	41	-17	94
30 Jun 23	43	-11	97
31 Mar 23	23	-55	57
31 Dec 22	44	-59	62
30 Sep 22	45	-74	68
30 Jun 22	41	-88	76
31 Mar 22	48	-98	64
31 Dec 21	34	-106	70
30 Sep 21	33	-111	73
30 Jun 21	78	-106	75
31 Mar 21	136	-160	69
31 Dec 20	134	-158	68
30 Sep 20	161	-162	72
30 Jun 20	166	-161	71
31 Mar 20	120	-49	62
31 Dec 19	119	-45	67
30 Sep 19	89	-38	56
30 Jun 19	44	-47	58
31 Mar 19	28	-42	75
31 Dec 18	25	-49	76
30 Sep 18	24	-58	85
30 Jun 18	25	-61	90
31 Mar 18	22	-156	108
31 Dec 17	24	-164	119
30 Sep 17	25	-172	130
30 Jun 17	26	-175	134
31 Mar 17	32	-223	169
31 Dec 16	29	-222	165
30 Sep 16	26	-218	160
30 Jun 16	35	-207	159
31 Mar 16	27	-63	101
31 Dec 15	78	-22	99
30 Sep 15	121	8	98
30 Jun 15	124	19	95
31 Mar 15	135	37	85
31 Dec 14	131	36	79
30 Sep 14	103	25	73
30 Jun 14	96	15	68
31 Mar 14	90	-11	70
31 Dec 13	52	-20	67

Kaliteli Kazançlar: 8156 şu anda kârlı değil.

Büyüyen Kar Marjı: 8156 şu anda kârlı değil.

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: 8156 kârlı değildir, ancak son 5 yılda zararlarını yılda 6.6% oranında azaltmıştır.

Büyüme Hızlandırma: 8156 'un son bir yıldaki kazanç büyümesinin 5 yıllık ortalamasıyla karşılaştırılması mümkün değil çünkü şu anda kârlı değil

Kazançlar vs. Sektör: 8156 kârlı olmadığından, geçmiş yıl kazanç büyümesinin Hospitality sektörüyle ( 12.6% ) karşılaştırılması zorlaşıyor.

Özkaynak Getirisi

Yüksek ROE: 8156 'un yükümlülükleri varlıklarından fazla olduğundan Özsermaye Getirisi'ni hesaplamak zordur.

Sinopharm Tech Holdings Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

Anahtar bilgiler

Yakın geçmiş performans güncellemeleri

Second quarter 2024 earnings released: HK$0.003 loss per share (vs HK$0.061 profit in 2Q 2023)

Sinopharm Tech Holdings Limited to Report First Half, 2024 Results on Feb 29, 2024

First quarter 2024 earnings released: HK$0.013 loss per share (vs HK$0.024 profit in 1Q 2023)

Sinopharm Tech Holdings Limited to Report Q1, 2024 Results on Nov 14, 2023

Full year 2023 earnings released: HK$0.001 loss per share (vs HK$0.49 loss in FY 2022)

Sinopharm Tech Holdings Limited to Report Fiscal Year 2023 Results on Sep 29, 2023

Recent updates

New minor risk - Financial data availability

Second quarter 2024 earnings released: HK$0.003 loss per share (vs HK$0.061 profit in 2Q 2023)

Sinopharm Tech Holdings Limited to Report First Half, 2024 Results on Feb 29, 2024

Sinopharm Tech Holdings Limited Announces Management Changes

Sinopharm Tech Holdings Limited, Annual General Meeting, Dec 22, 2023

First quarter 2024 earnings released: HK$0.013 loss per share (vs HK$0.024 profit in 1Q 2023)

Sinopharm Tech Holdings Limited to Report Q1, 2024 Results on Nov 14, 2023

Full year 2023 earnings released: HK$0.001 loss per share (vs HK$0.49 loss in FY 2022)

Sinopharm Tech Holdings Limited Provides Earnings Guidance for the Year Ended 30 June 2023

Sinopharm Tech Holdings Limited to Report Fiscal Year 2023 Results on Sep 29, 2023

Sinopharm Tech Holdings Limited Appoints HEUNG Pik Lun as an Independent Non-Executive Director and A Member of the Audit Committee and the Nomination Committee

New major risk - Share price stability

Third quarter 2023 earnings released: HK$0.001 loss per share (vs HK$0.002 loss in 3Q 2022)

Sinopharm Tech Holdings Limited Announces the Resignation of LAM Kit Sun as Independent Non-Executive Director, Member of the Audit Committee and the Remuneration Committee and the Chairperson and Member of the Nomination Committee

Second quarter 2023 earnings released: EPS: HK$0.002 (vs HK$0.001 loss in 2Q 2022)

Sinopharm Tech Holdings Provides Earnings Guidance for the Six Months Ended December 31, 2022

Sinopharm Tech Holdings Limited to Report First Half, 2023 Results on Feb 14, 2023

First quarter 2023 earnings released: EPS: HK$0.001 (vs HK$0.002 loss in 1Q 2022)

Less than half of directors are independent

Sinopharm Tech Holdings Limited, Annual General Meeting, Dec 16, 2022

Sinopharm Tech Holdings Limited Provides Unaudited Consolidated Earnings Guidance for the Three Months Ended 30 September 2022

Sinopharm Tech Holdings Limited to Report Q1, 2023 Results on Nov 14, 2022

Full year 2022 earnings released: HK$0.02 loss per share (vs HK$0.025 loss in FY 2021)

Sinopharm Tech Holdings Limited to Report Fiscal Year 2022 Results on Sep 30, 2022

Sinopharm Tech Holdings Limited Announces Management Changes

Sinopharm Tech Holdings Limited Announces Management Changes

Chan Ting Resigns as CEO of Sinopharm Tech Holdings Limited

Third quarter 2022 earnings released: HK$0.002 loss per share (vs HK$0.004 loss in 3Q 2021)

Less than half of directors are independent

Second quarter 2022 earnings: Revenues and EPS in line with analyst expectations

Sinopharm Tech Holdings Limited to Report First Half, 2022 Results on Feb 14, 2022

Sinopharm Tech Holdings Limited to Report First Half, 2022 Results on Feb 14, 2022

First quarter 2022 earnings released: HK$0.002 loss per share (vs HK$0.001 loss in 1Q 2021)

Full year 2021 earnings released: HK$0.025 loss per share (vs HK$0.039 loss in FY 2020)

Insider recently bought HK$15m worth of stock

Co-Founder & Non-Executive Director Tung Mei Chan has left the company

Third quarter 2021 earnings released: HK$0.004 loss per share (vs HK$0.004 loss in 3Q 2020)

Sinopharm Tech Holdings Limited (SEHK:8156) entered into a sale and purchase agreement to acquire 25% stake in Shenzhen Ficus Technology Holdings Ltd. from Sharp Associates Limited for HKD 200 million.

New 90-day high: HK$0.29

Second quarter 2021 earnings released: HK$0.002 loss per share (vs HK$0.003 loss in 2Q 2020)

Is Sinopharm Tech Holdings Limited's (HKG:8156) Shareholder Ownership Skewed Towards Insiders?

Sinopharm Tech Holdings Limited to Report First Half, 2021 Results on Feb 10, 2021

Sinopharm Tech Holdings Limited Announces Board Changes

New 90-day high: HK$0.22

How Much Did Sinopharm Tech Holdings'(HKG:8156) Shareholders Earn From Share Price Movements Over The Last Five Years?

New 90-day high: HK$0.20

How Should Investors Feel About Sinopharm Tech Holdings' (HKG:8156) CEO Remuneration?

First quarter 2021 earnings released: HK$0.001 loss per share

Sinopharm Tech Holdings Limited to Report Q1, 2021 Results on Nov 12, 2020

Full year earnings released - HK$0.039 loss per share

Sinopharm Tech Holdings Limited(SEHK:8156) dropped from S&P Global BMI Index

Sinopharm Tech Holdings Limited to Report Fiscal Year 2020 Results on Sep 29, 2020

Gelir ve Gider Dağılımı

Kazanç ve Gelir Geçmişi

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Özkaynak Getirisi

Varlık Getirisi

Kullanılan Sermaye Getirisi

Geçmişte güçlü performans gösteren şirketleri keşfedin